Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 62 entries
Sorted by: Best Match Show Resources per page
The Role of Topical Brimonidine Tartrate Gel as a Novel Therapeutic Option for Persistent Facial Erythema Associated with Rosacea.

Dermatology and therapy

Johnson AW, Johnson SM.
PMID: 26112098
Dermatol Ther (Heidelb). 2015 Sep;5(3):171-81. doi: 10.1007/s13555-015-0078-1. Epub 2015 Jun 26.

Rosacea is a chronic inflammatory skin condition that commonly presents with persistent facial erythema with or without the coincident presence of flushing, telangiectasias, inflammatory papules or pustules, phymatous changes, or ocular involvement. Patients often present with a constellation of...

Cite
Johnson AW, Johnson SM. The Role of Topical Brimonidine Tartrate Gel as a Novel Therapeutic Option for Persistent Facial Erythema Associated with Rosacea. Dermatol Ther (Heidelb). 2015;5(3):171-81doi: 10.1007/s13555-015-0078-1.
Johnson, A. W., & Johnson, S. M. (2015). The Role of Topical Brimonidine Tartrate Gel as a Novel Therapeutic Option for Persistent Facial Erythema Associated with Rosacea. Dermatology and therapy, 5(3), 171-81. https://doi.org/10.1007/s13555-015-0078-1
Johnson, Andrew William, and Johnson, Sandra Marchese. "The Role of Topical Brimonidine Tartrate Gel as a Novel Therapeutic Option for Persistent Facial Erythema Associated with Rosacea." Dermatology and therapy vol. 5,3 (2015): 171-81. doi: https://doi.org/10.1007/s13555-015-0078-1
Johnson AW, Johnson SM. The Role of Topical Brimonidine Tartrate Gel as a Novel Therapeutic Option for Persistent Facial Erythema Associated with Rosacea. Dermatol Ther (Heidelb). 2015 Sep;5(3):171-81. doi: 10.1007/s13555-015-0078-1. Epub 2015 Jun 26. PMID: 26112098; PMCID: PMC4580655.
Copy Download .nbib Format: NLM
Update on the management of rosacea.

Clinical, cosmetic and investigational dermatology

Weinkle AP, Doktor V, Emer J.
PMID: 25897253
Clin Cosmet Investig Dermatol. 2015 Apr 07;8:159-77. doi: 10.2147/CCID.S58940. eCollection 2015.

Refining diagnostic criteria has identified key characteristics differentiating rosacea, a chronic skin disorder, from other common cutaneous inflammatory conditions. The current classification system developed by the National Rosacea Society Expert Committee consists of erythematotelangiectatic, papulopustular, phymatous, and ocular subtypes....

Cite
Weinkle AP, Doktor V, Emer J. Update on the management of rosacea. Clin Cosmet Investig Dermatol. 2015;8:159-77doi: 10.2147/CCID.S58940.
Weinkle, A. P., Doktor, V., & Emer, J. (2015). Update on the management of rosacea. Clinical, cosmetic and investigational dermatology, 8159-77. https://doi.org/10.2147/CCID.S58940
Weinkle, Allison P, et al. "Update on the management of rosacea." Clinical, cosmetic and investigational dermatology vol. 8 (2015): 159-77. doi: https://doi.org/10.2147/CCID.S58940
Weinkle AP, Doktor V, Emer J. Update on the management of rosacea. Clin Cosmet Investig Dermatol. 2015 Apr 07;8:159-77. doi: 10.2147/CCID.S58940. eCollection 2015. PMID: 25897253; PMCID: PMC4396587.
Copy Download .nbib Format: NLM
Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology

Bayes M, Rabasseda X, Prous JR.
PMID: 16845450
Methods Find Exp Clin Pharmacol. 2006 Jun;28(5):323-43.

Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the following tables have been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug...

Cite
Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2006;28(5):323-43
Bayes, M., Rabasseda, X., & Prous, J. R. (2006). Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology, 28(5), 323-43.
Bayes, M, et al. "Gateways to clinical trials." Methods and findings in experimental and clinical pharmacology vol. 28,5 (2006): 323-43.
Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2006 Jun;28(5):323-43. PMID: 16845450.
Copy Download .nbib Format: NLM
Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology

Tomillero A, Moral MA.
PMID: 19967103
Methods Find Exp Clin Pharmacol. 2009 Oct;31(8):541-57.

[Methoxy-11c]PD-153035; Afamelanotide, Agalsidase beta, Alemtuzumab, Alkaline phosphatase, Amlodipine, Anecortave acetate, Apixaban, Aripiprazole, Atomoxetine hydrochloride; Bevacizumab, Bortezomib, Bosentan, Botulinum toxin type B, Brimonidine tartrate/timolol maleate, Brivudine; Canakinumab, Cetuximab, Chlorotoxin, Cinaciguat; Dapagliflozin, Decitabine, Duloxetine hydrochloride; Elagolix sodium, Eplerenone, Eritoran tetrasodium, Escitalopram...

Cite
Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2009;31(8):541-57
Tomillero, A., & Moral, M. A. (2009). Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology, 31(8), 541-57.
Tomillero, A, and Moral, M A. "Gateways to clinical trials." Methods and findings in experimental and clinical pharmacology vol. 31,8 (2009): 541-57.
Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2009 Oct;31(8):541-57. PMID: 19967103.
Copy Download .nbib Format: NLM
Spotlight on brimonidine topical gel 0.33% for facial erythema of rosacea: safety, efficacy, and patient acceptability.

Patient preference and adherence

Anderson MS, Nadkarni A, Cardwell LA, Alinia H, Feldman SR.
PMID: 28740369
Patient Prefer Adherence. 2017 Jul 06;11:1143-1150. doi: 10.2147/PPA.S115708. eCollection 2017.

BACKGROUND: Brimonidine tartrate is a highly selective alpha 2 agonist that induces direct vasoconstriction of small arteries and veins, thereby reducing vasodilation and edema.OBJECTIVE: To review the current literature regarding the safety, efficacy, and patient acceptability of brimonidine 0.33%...

Cite
Anderson MS, Nadkarni A, Cardwell LA, et al. Spotlight on brimonidine topical gel 0.33% for facial erythema of rosacea: safety, efficacy, and patient acceptability. Patient Prefer Adherence. 2017;11:1143-1150doi: 10.2147/PPA.S115708.
Anderson, M. S., Nadkarni, A., Cardwell, L. A., Alinia, H., & Feldman, S. R. (2017). Spotlight on brimonidine topical gel 0.33% for facial erythema of rosacea: safety, efficacy, and patient acceptability. Patient preference and adherence, 111143-1150. https://doi.org/10.2147/PPA.S115708
Anderson, Michael S, et al. "Spotlight on brimonidine topical gel 0.33% for facial erythema of rosacea: safety, efficacy, and patient acceptability." Patient preference and adherence vol. 11 (2017): 1143-1150. doi: https://doi.org/10.2147/PPA.S115708
Anderson MS, Nadkarni A, Cardwell LA, Alinia H, Feldman SR. Spotlight on brimonidine topical gel 0.33% for facial erythema of rosacea: safety, efficacy, and patient acceptability. Patient Prefer Adherence. 2017 Jul 06;11:1143-1150. doi: 10.2147/PPA.S115708. eCollection 2017. PMID: 28740369; PMCID: PMC5505675.
Copy Download .nbib Format: NLM
Use of brimonidine tartrate to resolve telangiectatic matting: case report.

Jornal vascular brasileiro

de Mello BAS, Beiriz YR, Bonatto AC, Maciel GSB, de Almeida LR, Corassa JM.
PMID: 34290750
J Vasc Bras. 2020 Sep 14;19:e20190159. doi: 10.1590/1677-5449.190159. eCollection 2020.

Sclerotherapy is currently the treatment of choice for telangiectasias and reticular veins, with grade 1A recommendation in the European Guideline for sclerotherapy. The most common side effects of this procedure are hyperpigmentation and telangiectatic matting, the second of which...

Cite
de Mello BAS, Beiriz YR, Bonatto AC, et al. Use of brimonidine tartrate to resolve telangiectatic matting: case report. J Vasc Bras. 2020;19:e20190159doi: 10.1590/1677-5449.190159.
de Mello, B. A. S., Beiriz, Y. R., Bonatto, A. C., Maciel, G. S. B., de Almeida, L. R., & Corassa, J. M. (2020). Use of brimonidine tartrate to resolve telangiectatic matting: case report. Jornal vascular brasileiro, 19e20190159. https://doi.org/10.1590/1677-5449.190159
de Mello, Brenno Augusto Seabra, et al. "Use of brimonidine tartrate to resolve telangiectatic matting: case report." Jornal vascular brasileiro vol. 19 (2020): e20190159. doi: https://doi.org/10.1590/1677-5449.190159
de Mello BAS, Beiriz YR, Bonatto AC, Maciel GSB, de Almeida LR, Corassa JM. Use of brimonidine tartrate to resolve telangiectatic matting: case report. J Vasc Bras. 2020 Sep 14;19:e20190159. doi: 10.1590/1677-5449.190159. eCollection 2020. PMID: 34290750; PMCID: PMC8276647.
Copy Download .nbib Format: NLM
Ocular metabolism and distribution of drugs in the rabbit eye: Quantitative assessment after intracameral and intravitreal administrations.

International journal of pharmaceutics

Del Amo EM, Hammid A, Tausch M, Toropainen E, Sadeghi A, Valtari A, Puranen J, Reinisalo M, Ruponen M, Urtti A, Sauer A, Honkakoski P.
PMID: 34896561
Int J Pharm. 2021 Dec 09;613:121361. doi: 10.1016/j.ijpharm.2021.121361. Epub 2021 Dec 09.

Quantitation of ocular drug metabolism is important, but only sparse data is currently available. Herein, the pharmacokinetics of four drugs, substrates of metabolizing enzymes, was investigated in albino rabbit eyes after intracameral and intravitreal administrations. Acetaminophen, brimonidine, cefuroxime axetil,...

Cite
Del Amo EM, Hammid A, Tausch M, et al. Ocular metabolism and distribution of drugs in the rabbit eye: Quantitative assessment after intracameral and intravitreal administrations. Int J Pharm. 2021;613:121361doi: 10.1016/j.ijpharm.2021.121361.
Del Amo, E. M., Hammid, A., Tausch, M., Toropainen, E., Sadeghi, A., Valtari, A., Puranen, J., Reinisalo, M., Ruponen, M., Urtti, A., Sauer, A., & Honkakoski, P. (2021). Ocular metabolism and distribution of drugs in the rabbit eye: Quantitative assessment after intracameral and intravitreal administrations. International journal of pharmaceutics, 613121361. https://doi.org/10.1016/j.ijpharm.2021.121361
Del Amo, Eva M, et al. "Ocular metabolism and distribution of drugs in the rabbit eye: Quantitative assessment after intracameral and intravitreal administrations." International journal of pharmaceutics vol. 613 (2021): 121361. doi: https://doi.org/10.1016/j.ijpharm.2021.121361
Del Amo EM, Hammid A, Tausch M, Toropainen E, Sadeghi A, Valtari A, Puranen J, Reinisalo M, Ruponen M, Urtti A, Sauer A, Honkakoski P. Ocular metabolism and distribution of drugs in the rabbit eye: Quantitative assessment after intracameral and intravitreal administrations. Int J Pharm. 2021 Dec 09;613:121361. doi: 10.1016/j.ijpharm.2021.121361. Epub 2021 Dec 09. PMID: 34896561.
Copy Download .nbib Format: NLM
Ocular metabolism and distribution of drugs in the rabbit eye: Quantitative assessment after intracameral and intravitreal administrations.

International journal of pharmaceutics

Del Amo EM, Hammid A, Tausch M, Toropainen E, Sadeghi A, Valtari A, Puranen J, Reinisalo M, Ruponen M, Urtti A, Sauer A, Honkakoski P.
PMID: 34896561
Int J Pharm. 2021 Dec 09;613:121361. doi: 10.1016/j.ijpharm.2021.121361. Epub 2021 Dec 09.

Quantitation of ocular drug metabolism is important, but only sparse data is currently available. Herein, the pharmacokinetics of four drugs, substrates of metabolizing enzymes, was investigated in albino rabbit eyes after intracameral and intravitreal administrations. Acetaminophen, brimonidine, cefuroxime axetil,...

Cite
Del Amo EM, Hammid A, Tausch M, et al. Ocular metabolism and distribution of drugs in the rabbit eye: Quantitative assessment after intracameral and intravitreal administrations. Int J Pharm. 2021;613:121361doi: 10.1016/j.ijpharm.2021.121361.
Del Amo, E. M., Hammid, A., Tausch, M., Toropainen, E., Sadeghi, A., Valtari, A., Puranen, J., Reinisalo, M., Ruponen, M., Urtti, A., Sauer, A., & Honkakoski, P. (2021). Ocular metabolism and distribution of drugs in the rabbit eye: Quantitative assessment after intracameral and intravitreal administrations. International journal of pharmaceutics, 613121361. https://doi.org/10.1016/j.ijpharm.2021.121361
Del Amo, Eva M, et al. "Ocular metabolism and distribution of drugs in the rabbit eye: Quantitative assessment after intracameral and intravitreal administrations." International journal of pharmaceutics vol. 613 (2021): 121361. doi: https://doi.org/10.1016/j.ijpharm.2021.121361
Del Amo EM, Hammid A, Tausch M, Toropainen E, Sadeghi A, Valtari A, Puranen J, Reinisalo M, Ruponen M, Urtti A, Sauer A, Honkakoski P. Ocular metabolism and distribution of drugs in the rabbit eye: Quantitative assessment after intracameral and intravitreal administrations. Int J Pharm. 2021 Dec 09;613:121361. doi: 10.1016/j.ijpharm.2021.121361. Epub 2021 Dec 09. PMID: 34896561.
Copy Download .nbib Format: NLM
Corneal Opacity Induced by Antiglaucoma Agents Other Than Brimonidine Tartrate.

Case reports in ophthalmological medicine

Kasuya Y, Sano I, Makino S, Kawashima H.
PMID: 32547800
Case Rep Ophthalmol Med. 2020 May 26;2020:4803651. doi: 10.1155/2020/4803651. eCollection 2020.

The aim of this study is to report a patient with corneal opacity that developed after the use of topical antiglaucoma medications other than brimonidine tartrate (BT). An 85-year-old woman presented with corneal opacity and neovascularization in both eyes....

Cite
Kasuya Y, Sano I, Makino S, et al. Corneal Opacity Induced by Antiglaucoma Agents Other Than Brimonidine Tartrate. Case Rep Ophthalmol Med. 2020;2020:4803651doi: 10.1155/2020/4803651.
Kasuya, Y., Sano, I., Makino, S., & Kawashima, H. (2020). Corneal Opacity Induced by Antiglaucoma Agents Other Than Brimonidine Tartrate. Case reports in ophthalmological medicine, 20204803651. https://doi.org/10.1155/2020/4803651
Kasuya, Yuka, et al. "Corneal Opacity Induced by Antiglaucoma Agents Other Than Brimonidine Tartrate." Case reports in ophthalmological medicine vol. 2020 (2020): 4803651. doi: https://doi.org/10.1155/2020/4803651
Kasuya Y, Sano I, Makino S, Kawashima H. Corneal Opacity Induced by Antiglaucoma Agents Other Than Brimonidine Tartrate. Case Rep Ophthalmol Med. 2020 May 26;2020:4803651. doi: 10.1155/2020/4803651. eCollection 2020. PMID: 32547800; PMCID: PMC7273428.
Copy Download .nbib Format: NLM
Fast Dissolving Dendrimer Nanofiber Mats as Alternative to Eye Drops for More Efficient Antiglaucoma Drug Delivery.

ACS biomaterials science & engineering

Lancina MG, Singh S, Kompella UB, Husain S, Yang H.
PMID: 29152562
ACS Biomater Sci Eng. 2017 Aug 14;3(8):1861-1868. doi: 10.1021/acsbiomaterials.7b00319. Epub 2017 Jun 09.

Polyamidoamine (PAMAM) dendrimers have been investigated as a potential platform for a number of ocular drugs, but only in aqueous solution. In this work we have developed fast dissolving dendrimer-based nanofibers (DNF) as a topical delivery vehicle for the...

Cite
Lancina MG, Singh S, Kompella UB, et al. Fast Dissolving Dendrimer Nanofiber Mats as Alternative to Eye Drops for More Efficient Antiglaucoma Drug Delivery. ACS Biomater Sci Eng. 2017;3(8):1861-1868doi: 10.1021/acsbiomaterials.7b00319.
Lancina, M. G., Singh, S., Kompella, U. B., Husain, S., & Yang, H. (2017). Fast Dissolving Dendrimer Nanofiber Mats as Alternative to Eye Drops for More Efficient Antiglaucoma Drug Delivery. ACS biomaterials science & engineering, 3(8), 1861-1868. https://doi.org/10.1021/acsbiomaterials.7b00319
Lancina, Michael G, et al. "Fast Dissolving Dendrimer Nanofiber Mats as Alternative to Eye Drops for More Efficient Antiglaucoma Drug Delivery." ACS biomaterials science & engineering vol. 3,8 (2017): 1861-1868. doi: https://doi.org/10.1021/acsbiomaterials.7b00319
Lancina MG, Singh S, Kompella UB, Husain S, Yang H. Fast Dissolving Dendrimer Nanofiber Mats as Alternative to Eye Drops for More Efficient Antiglaucoma Drug Delivery. ACS Biomater Sci Eng. 2017 Aug 14;3(8):1861-1868. doi: 10.1021/acsbiomaterials.7b00319. Epub 2017 Jun 09. PMID: 29152562; PMCID: PMC5685521.
Copy Download .nbib Format: NLM
Intraocular pressure reduction using a fixed combination of timolol maleate 0.5% and brimonidine tartrate 0.2% administered three times daily.

Clinical ophthalmology (Auckland, N.Z.)

Moisseiev E, Kurtz S, Lazar M, Shemesh G.
PMID: 23836956
Clin Ophthalmol. 2013;7:1269-73. doi: 10.2147/OPTH.S47760. Epub 2013 Jun 25.

BACKGROUND: The purpose of this study was to evaluate the safety and efficacy of a fixed combination of timolol maleate 0.5% + brimonidine tartrate 0.2% (Combigan®) for reduction for intraocular pressure (IOP) in patients with glaucoma when the dose...

Cite
Moisseiev E, Kurtz S, Lazar M, et al. Intraocular pressure reduction using a fixed combination of timolol maleate 0.5% and brimonidine tartrate 0.2% administered three times daily. Clin Ophthalmol. 2013;7:1269-73doi: 10.2147/OPTH.S47760.
Moisseiev, E., Kurtz, S., Lazar, M., & Shemesh, G. (2013). Intraocular pressure reduction using a fixed combination of timolol maleate 0.5% and brimonidine tartrate 0.2% administered three times daily. Clinical ophthalmology (Auckland, N.Z.), 71269-73. https://doi.org/10.2147/OPTH.S47760
Moisseiev, Elad, et al. "Intraocular pressure reduction using a fixed combination of timolol maleate 0.5% and brimonidine tartrate 0.2% administered three times daily." Clinical ophthalmology (Auckland, N.Z.) vol. 7 (2013): 1269-73. doi: https://doi.org/10.2147/OPTH.S47760
Moisseiev E, Kurtz S, Lazar M, Shemesh G. Intraocular pressure reduction using a fixed combination of timolol maleate 0.5% and brimonidine tartrate 0.2% administered three times daily. Clin Ophthalmol. 2013;7:1269-73. doi: 10.2147/OPTH.S47760. Epub 2013 Jun 25. PMID: 23836956; PMCID: PMC3699296.
Copy Download .nbib Format: NLM
Update on the Management of Rosacea.

Plastic surgical nursing : official journal of the American Society of Plastic and Reconstructive Surgical Nurses

Weinkle AP, Doktor V, Emer J.
PMID: 26605825
Plast Surg Nurs. 2015 Oct-Dec;35(4):184-202. doi: 10.1097/PSN.0000000000000111.

Refining diagnostic criteria has identified key characteristics differentiating rosacea, a chronic skin disorder, from other common cutaneous inflammatory conditions. The current classification system developed by the National Rosacea Society Expert Committee consists of erythematotelangiectatic, papulopustular, phymatous, and ocular subtypes....

Cite
Weinkle AP, Doktor V, Emer J. Update on the Management of Rosacea. Plast Surg Nurs. 2015;35(4):184-202doi: 10.1097/PSN.0000000000000111.
Weinkle, A. P., Doktor, V., & Emer, J. (2015). Update on the Management of Rosacea. Plastic surgical nursing : official journal of the American Society of Plastic and Reconstructive Surgical Nurses, 35(4), 184-202. https://doi.org/10.1097/PSN.0000000000000111
Weinkle, Allison P, et al. "Update on the Management of Rosacea." Plastic surgical nursing : official journal of the American Society of Plastic and Reconstructive Surgical Nurses vol. 35,4 (2015): 184-202. doi: https://doi.org/10.1097/PSN.0000000000000111
Weinkle AP, Doktor V, Emer J. Update on the Management of Rosacea. Plast Surg Nurs. 2015 Oct-Dec;35(4):184-202. doi: 10.1097/PSN.0000000000000111. PMID: 26605825.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 62 entries